Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Anniko (penpulimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Akesobio, Sino Biopharm, Specialised Therap

Drug class:

PD1 inhibitor

Related drugs:

pembrolizumab (727)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (7)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

ivonescimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

nivolumab and hyaluronidase-nvhy (0)

PD-1-KO-T cell injection (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	penpulimab Sensitive: B - Late Trials penpulimab Sensitive : B	penpulimab Sensitive: B - Late Trials penpulimab Sensitive : B
PD-L1 expression	Nasopharyngeal Carcinoma	PD-L1 expression	Nasopharyngeal Carcinoma	penpulimab Sensitive: C2 – Inclusion Criteria penpulimab Sensitive : C2	penpulimab Sensitive: C2 – Inclusion Criteria penpulimab Sensitive : C2
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	anlotinib + penpulimab Sensitive: C2 – Inclusion Criteria anlotinib + penpulimab Sensitive : C2	anlotinib + penpulimab Sensitive: C2 – Inclusion Criteria anlotinib + penpulimab Sensitive : C2
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide + penpulimab Sensitive: C3 – Early Trials rituximab + lenalidomide + penpulimab Sensitive : C3	rituximab + lenalidomide + penpulimab Sensitive: C3 – Early Trials rituximab + lenalidomide + penpulimab Sensitive : C3
IFNG overexpression	Pancreatic Cancer	IFNG overexpression	Pancreatic Cancer	anlotinib + penpulimab Sensitive: C3 – Early Trials anlotinib + penpulimab Sensitive : C3	anlotinib + penpulimab Sensitive: C3 – Early Trials anlotinib + penpulimab Sensitive : C3